SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-027064
Filing Date
2022-05-16
Accepted
2022-05-16 16:01:21
Documents
52
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0322_vickersvantage1.htm   iXBRL 10-Q 474197
2 CERTIFICATION f10q0322ex31-1_vickers1.htm EX-31.1 13631
3 CERTIFICATION f10q0322ex31-2_vickers1.htm EX-31.2 12061
4 CERTIFICATION f10q0322ex32-1_vickers1.htm EX-32.1 4885
5 CERTIFICATION f10q0322ex32-2_vickers1.htm EX-32.2 5267
  Complete submission text file 0001213900-22-027064.txt   3102981

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE vcka-20220331.xsd EX-101.SCH 39972
7 XBRL CALCULATION FILE vcka-20220331_cal.xml EX-101.CAL 22106
8 XBRL DEFINITION FILE vcka-20220331_def.xml EX-101.DEF 164887
9 XBRL LABEL FILE vcka-20220331_lab.xml EX-101.LAB 310275
10 XBRL PRESENTATION FILE vcka-20220331_pre.xml EX-101.PRE 172563
46 EXTRACTED XBRL INSTANCE DOCUMENT f10q0322_vickersvantage1_htm.xml XML 311734
Mailing Address 85 BROAD STREET, 29TH FLOOR NEW YORK NY 10004
Business Address 85 BROAD STREET, 29TH FLOOR NEW YORK NY 10004 (646) 974-8301
Vickers Vantage Corp. I (Filer) CIK: 0001820190 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39852 | Film No.: 22928479
SIC: 2836 Biological Products, (No Diagnostic Substances)